Vaccine Formulation and Manufacturing for High-Density Microarray Patches (HD-MAPs): Challenges in Replacing the Needle and Syringe

Dr Forster has worked in medical product development and commercialization for 20 years and has overall responsibility for the research, development and operations of Vaxxas. Since 2012, Angus has established the Vaxxas R&D team that includes more than 70 scientists, engineers and professional staff, and led three Phase I clinical studies. He brings considerable experience in pharmaceutics, formulation development, analytical science, medical device design and development, risk management and quality systems.  Before joining Vaxxas, Angus commenced his career with GlaxoSmithKline in pharmaceutical development and spent 5 years with PA Consulting (UK) working medical product development projects.  Angus has Ph.D. in pharmaceutics and a B.Pharm (Hons) both from Otago University, New Zealand.